Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M57.5Revenue (TTM) $M9.5Net Margin (%)-166.1Altman Z-Score-7.3
Enterprise Value $M48.1EPS (TTM) $-3.1Operating Margin %-158.5Piotroski F-Score4
P/E(ttm)--Beneish M-Score0.2Pre-tax Margin (%)-166.1Higher ROA y-yN
Price/Book8.410-y EBITDA Growth Rate %--Quick Ratio3.6Cash flow > EarningsN
Price/Sales2.35-y EBITDA Growth Rate %16.9Current Ratio3.9Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-202.2Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M15.1ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with NBY

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

NBY is held by these investors:



NBY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Najafi RaminCEO, 10% Owner 2015-08-20Buy480$11.75-67.66view
Pioneer Pharma (Singapore) Pte10% Owner 2015-03-03Buy103,600$15-74.67view
SIECZKAREK MARK MDirector 2015-03-03Buy6,667$15-74.67view
Najafi RaminChairman 2015-03-03Buy6,667$15-74.67view
Najafi RaminChairman 2014-12-12Buy2,000$16.25-76.62view
PAULSON THOMAS JCFO 2014-12-12Buy400$17-77.65view
Stroman David W.SVP, Ophthalmic Product Devt. 2014-12-12Buy400$16.5-76.97view
Najafi RaminChairman 2014-12-11Buy800$15-74.67view
PAULSON THOMAS JCFO 2014-12-09Buy400$16.75-77.31view
Najafi RaminChairman 2014-12-05Buy1,000$16.25-76.62view

Press Releases about NBY :

Quarterly/Annual Reports about NBY:

News about NBY:

Articles On GuruFocus.com
NovaBay Pharmaceuticals Inc. (NBY) Chairman Ramin Najafi buys 1,000 Shares Aug 28 2009 

More From Other Websites
Relief from Painful Dry Eye Can be a Real Valentine's Day Gift Feb 14 2017
Coverage initiated on NovaBay Pharma by Rodman & Renshaw Feb 06 2017
NovaBay CEO Sees Continued Double-Digit Revenue Growth in 2017 Jan 30 2017
NovaBay Pharmaceuticals' "Avenova" Helping Patients with Contact Lens Intolerance Jan 27 2017
NovaBay Pharmaceuticals Announces Preliminary Sales for the Fourth Quarter of 2016 Jan 09 2017
NovaBay's Avenova Brings Quick Relief to Children Suffering from Eye Conditions, Writes Steven J.... Dec 19 2016
NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Dec 19 2016
NovaBay to Present at LD Micro Main Event Dec 01 2016
MULTIMEDIA UPDATE - NovaBay's Avenova Is Breakthrough in Fight Against Contact Lens Intolerance Nov 29 2016
NovaBay's Avenova Is Breakthrough in Fight Against Contact Lens Intolerance Nov 29 2016
Five Stocks Under $5.00 for December (NAK, GGB) Nov 23 2016
NOVABAY PHARMACEUTICALS, INC. Financials Nov 18 2016
NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14,... Nov 14 2016
NovaBay Pharmaceuticals Reports 2016 Third Quarter Financial Results Nov 10 2016
NOVABAY PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Nov 10 2016
NovaBay Pharmaceuticals Reports 2016 Third Quarter Financial Results Nov 10 2016
NovaBay Pharmaceuticals to Hold Third Quarter 2016 Conference Call on November 10 Nov 04 2016
NovaBay Pharmaceuticals to Hold Third Quarter 2016 Conference Call on November 10 Nov 03 2016
NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 31 2016
NovaBay Pharmaceuticals Successfully Regains Compliance with NYSE Continued Listing Requirements Oct 31 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)